Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
Open Access
- 12 July 2021
- Vol. 71 (3), 457-466
- https://doi.org/10.1136/gutjnl-2020-323392
Abstract
Objective In this study, we determined whether Helicobacter pylori (H. pylori) infection dampens the efficacy of cancer immunotherapies. Design Using mouse models, we evaluated whether immune checkpoint inhibitors or vaccine-based immunotherapies are effective in reducing tumour volumes of H. pylori-infected mice. In humans, we evaluated the correlation between H. pylori seropositivity and the efficacy of the programmed cell death protein 1 (PD-1) blockade therapy in patients with non-small-cell lung cancer (NSCLC). Results In mice engrafted with MC38 colon adenocarcinoma or B16-OVA melanoma cells, the tumour volumes of non-infected mice undergoing anticytotoxic T-lymphocyte-associated protein 4 and/or programmed death ligand 1 or anti-cancer vaccine treatments were significantly smaller than those of infected mice. We observed a decreased number and activation status of tumour-specific CD8+ T cells in the tumours of infected mice treated with cancer immunotherapies independent of the gut microbiome composition. Additionally, by performing an in vitro co-culture assay, we observed that dendritic cells of infected mice promote lower tumour-specific CD8+ T cell proliferation. We performed retrospective human clinical studies in two independent cohorts. In the Dijon cohort, H. pylori seropositivity was found to be associated with a decreased NSCLC patient survival on anti-PD-1 therapy. The survival median for H. pylori seropositive patients was 6.7 months compared with 15.4 months for seronegative patients (p=0.001). Additionally, in the Montreal cohort, H. pylori seropositivity was found to be associated with an apparent decrease of NSCLC patient progression-free survival on anti-PD-1 therapy. Conclusion Our study unveils for the first time that the stomach microbiota affects the response to cancer immunotherapies and that H. pylori serology would be a powerful tool to personalize cancer immunotherapy treatment.Keywords
Funding Information
- Foundation Emma Muschamp (NA)
- Faculté de Biologie et de Médecine de Lausanne (NA)
- Foundation Max Cloëtta (NA)
- Swiss Cancer Research Foundation (KFS-4452-02-2018; KFS-4840-08-2019)
- Foundation Porphyrogenis (NA)
This publication has 51 references indexed in Scilit:
- Helicobacter pylori γ-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune toleranceProceedings of the National Academy of Sciences of the United States of America, 2013
- DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori–specific immune tolerance, and asthma protectionJCI Insight, 2012
- Inverse Association of Esophageal Eosinophilia With Helicobacter pylori Based on Analysis of a US Pathology DatabaseGastroenterology, 2011
- Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cellsJCI Insight, 2011
- Comparative Whole Genome Sequence Analysis of the Carcinogenic Bacterial Model Pathogen Helicobacter felisGenome Biology and Evolution, 2011
- Association between Helicobacter pylori infection and inflammatory bowel diseaseInflammatory Bowel Diseases, 2010
- Induction of Intestinal Th17 Cells by Segmented Filamentous BacteriaCell, 2009
- Interleukin-17 Is a Critical Mediator of Vaccine-Induced Reduction of Helicobacter Infection in the Mouse ModelGastroenterology, 2009
- Helicobacter pyloriColonization Is Inversely Associated with Childhood AsthmaThe Journal of Infectious Diseases, 2008
- Gastric Transitional Zones, Areas whereHelicobacterTreatment Fails: Results of a Treatment Trial Using the Sydney Strain Mouse ModelAntimicrobial Agents and Chemotherapy, 2003